The 10q26 chromosomal locus is the second strongest genetic risk factor for age-related macular degeneration (AMD), second only to the complement factor H (CFH) gene on chromosome 1. Within the 10q26 locus sit two genes in strong linkage disequilibrium: ARMS2 (also called LOC387715) and HTRA1. rs2672598 is a promoter variant in HTRA1 — specifically a T-to-C change at position −487 relative to the transcription start site — that fundamentally alters how much HTRA1 serine protease the retina produces.

HTRA1 encodes a secreted serine protease that degrades extracellular matrix components and inhibits TGF-β signaling¹¹ TGF-β signaling
transforming growth factor beta, which controls blood vessel growth and tissue remodeling. In the eye, excess HTRA1 activity disrupts Bruch's membrane integrity and promotes the abnormal choroidal neovascularization that defines wet AMD — the rapidly vision-threatening form of the disease.

The Mechanism

The C allele at rs2672598 alters transcription factor binding at the HTRA1 promoter. The wild-type T allele creates binding sites for STAT4, NFκB, c-Ets-1, RelA, Elk-1, and WT1. The C allele replaces these with binding sites for GR-alpha, AP-2αA, and Sp1 — a different set of transcription factors that drive substantially higher HTRA1 transcriptional output. Luciferase reporter assays showed C-containing haplotypes had 1.78–1.99 fold higher promoter activity than wild-type T-containing haplotypes.

At the protein level, this translates directly to higher HTRA1 enzyme in the eye: vitreous humor HTRA1 protein in CC homozygotes was 2.56-fold higher than in TT homozygotes (P=0.02)²² vitreous humor HTRA1 protein in CC homozygotes was 2.56-fold higher than in TT homozygotes (P=0.02)
Nakanishi et al. HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative AMD. Sci Rep. 2016. This excess protease degrades extracellular matrix proteins including fibronectin and vitronectin³³ vitronectin
a glycoprotein that stabilizes Bruch's membrane and regulates complement activation in the subretinal space, weakening the barrier that separates the retinal pigment epithelium from the choroidal vasculature. Excess HTRA1 also cleaves LTBP-1, releasing TGF-β from its latent complex and amplifying pro-angiogenic signaling — the molecular basis of choroidal neovascularization.

rs2672598 is in strong linkage disequilibrium with rs11200638 (−625G>A in the same promoter), the most-studied HTRA1 AMD variant. Both variants are part of a risk haplotype that spans the HTRA1 promoter and exon 1 (ACCTT haplotype, P=6.68×10⁻¹⁴ for AMD association).

The Evidence

The most comprehensive single-study data for rs2672598 comes from Tam et al. 2008⁴⁴ Tam et al. 2008
HTRA1 variants in exudative age-related macular degeneration and interactions with smoking and CFH. Invest Ophthalmol Vis Sci. 2008, which genotyped 163 AMD cases and 183 controls from a Hong Kong Chinese population. The CC genotype conferred a 25.6-fold increased AMD risk compared to TT (OR=25.61, 95% CI: 3.36–195.05, P=3.03×10⁻¹⁰). The CT heterozygous genotype showed intermediate risk. Population-attributable risk for the HTRA1 haplotype alone was 53.1%.

Meta-analyses of the more-studied rs11200638 variant (in near-perfect LD with rs2672598) yield consistent effect sizes across all populations: AA homozygotes have 7.5–8.5-fold increased AMD risk versus GG controls; AG heterozygotes have 2.1–2.2-fold increased risk. A 2020 comprehensive meta-analysis of 15,316 subjects⁵⁵ 2020 comprehensive meta-analysis of 15,316 subjects
HTRA1 rs11200638 variant and AMD risk: comprehensive analysis. BMC Ophthalmol. 2020 confirmed these effects across European and Asian populations.

The association is specific to neovascular (wet) AMD — not dry AMD or geographic atrophy in isolation. Within wet AMD subtypes, Nakanishi et al. 2016⁶⁶ Nakanishi et al. 2016
HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative AMD. Sci Rep. 2016 demonstrated that rs2672598 CC specifically predicts exudative AMD (OR=10.53, P=1.31×10⁻⁴) much more strongly than polypoidal choroidal vasculopathy (OR=1.94 in meta-analysis, P=0.02), distinguishing it from other ARMS2 region variants.

Practical Actions

The CC genotype represents one of the highest monogenic risk increases for any common late-onset disease — a more-than-25-fold elevation in wet AMD risk. The most important actions are early detection and monitoring. Anti-VEGF therapy (ranibizumab, bevacizumab, aflibercept) is highly effective for wet AMD when started before significant vision loss — making the time between first symptoms and treatment the critical window.

Smoking is an independent multiplicative risk factor: HTRA1 risk allele carriers who smoke have compounded risk (OR ~15.7 for the combination vs baseline). Smoking cessation is therefore specifically relevant — not generically healthy advice, but a direct interaction with the HTRA1 pathway.

Lutein, zeaxanthin, and omega-3 fatty acids have been studied in the AREDS2 trial for AMD prevention and progression reduction. These are particularly relevant for high-HTRA1-risk genotypes because they protect the macular photoreceptors and retinal pigment epithelium that HTRA1-mediated matrix degradation makes vulnerable.

Interactions

rs2672598 is in strong LD with rs11200638 (HTRA1 promoter −625G>A) — both are part of the same risk haplotype and effects are not independent. Users carrying risk alleles at both loci are carrying the same underlying haplotype, not an additive combination.

The 10q26 HTRA1/ARMS2 locus interacts multiplicatively with the complement factor H gene (CFH rs1061170/rs800292, chromosome 1q32). The joint effect of homozygous risk at HTRA1 and CFH reaches OR=23.3 (95% CI: 2.5–218.2) with a combined population- attributable risk of 78.4% — meaning these two loci together explain the majority of genetic AMD risk in Western populations. Individuals carrying high-risk genotypes at rs1061170⁷⁷ rs1061170 in addition to rs2672598 CC should be considered at very high risk and are strong candidates for regular ophthalmic screening.

ARMS2 rs10490924 (the other major 10q26 variant, G>T) tags an overlapping haplotype and shows similar effect sizes to HTRA1. Because ARMS2 and HTRA1 are in high LD, rs10490924 and rs2672598 are correlated but non-identical — distinct SNPs capturing slightly different aspects of the 10q26 risk architecture.

The CYP1B1 gene encodes cytochrome P450 1B1¹¹ cytochrome P450 1B1
a monooxygenase enzyme involved in the oxidative metabolism of steroids, retinoids, polycyclic aromatic hydrocarbons, and other endogenous compounds. It is expressed broadly but is especially important in anterior eye segment tissues during fetal development. The Arg469Trp substitution at rs28936701 is one of the most clinically significant missense variants in CYP1B1 — a pathogenic mutation that disrupts the enzyme's catalytic function and is a well-established cause of primary congenital glaucoma (PCG)²² primary congenital glaucoma (PCG)
a rare inherited form of glaucoma presenting at birth or in the first year of life, characterized by elevated intraocular pressure and progressive optic nerve damage.

PCG is an autosomal recessive disease: two pathogenic CYP1B1 alleles are required for affected status. Individuals carrying a single copy of the Arg469Trp allele (heterozygous carriers) have normal vision but may pass the variant to their children.

The Mechanism

CYP1B1 is expressed in the trabecular meshwork and other anterior segment tissues during eye development. Loss of its enzymatic activity is thought to disrupt the metabolism of steroid signaling molecules critical for anterior segment morphogenesis³³ steroid signaling molecules critical for anterior segment morphogenesis
possibly including steroids involved in trabecular meshwork differentiation and aqueous humor outflow pathway development. When both copies of CYP1B1 are non-functional, the trabecular meshwork fails to develop correctly, blocking aqueous humor drainage and causing the elevated intraocular pressure that defines congenital glaucoma.

The Arg469Trp substitution sits in the heme-binding region of the protein. Unlike some CYP1B1 mutations that destabilize the protein, Jansson et al. showed the R469W holoenzyme is paradoxically stabilized⁴⁴ Jansson et al. showed the R469W holoenzyme is paradoxically stabilized
yet its catalytic activity against steroid substrates including testosterone, progesterone, and estradiol is substantially impaired, with altered metabolite profiles compared to wild-type. Mammen et al. confirmed that R469W reduces CYP1B1 activity against carcinogen substrates to only 3–12% of wild-type levels⁵⁵ 3–12% of wild-type levels
a near-complete functional knockout of enzymatic capacity.

The Evidence

CYP1B1 mutations were first established as the predominant cause of PCG in Saudi Arabia by Bejjani et al. 1998⁶⁶ Bejjani et al. 1998
establishing linkage to the GLC3A locus on chromosome 2p21 in 24 of 25 Saudi families. A follow-up study found that G61E, R469W, and D374N account for 72%, 12%, and 7% respectively of all PCG chromosomes in Saudi families⁷⁷ G61E, R469W, and D374N account for 72%, 12%, and 7% respectively of all PCG chromosomes in Saudi families
with R469W emerging as the second most common founder mutation in this population. Incomplete penetrance was documented — 40 unaffected individuals from 22 families carried identical mutations to affected siblings — suggesting a modifier locus can suppress disease expression.

In Iran, Chitsazian et al. 2007⁸⁸ Chitsazian et al. 2007
examining 104 Iranian PCG patients identified R469W as one of four mutations collectively comprising 76.2% of CYP1B1 mutated alleles in this population. Badeeb et al. 2014⁹⁹ Badeeb et al. 2014
studying 34 Saudi PCG patients found R469W homozygous in 14.8% of genetically solved cases, with severe disease phenotype; 30% of the ten most severe cases carried homozygous R469W. Rauf et al. 2016¹⁰¹⁰ Rauf et al. 2016
analyzing 23 Pakistani PCG families confirmed R469W's presence across South Asian and Middle Eastern populations.

Beyond glaucoma, CYP1B1 metabolizes 17β-estradiol to 4-hydroxyestradiol¹¹¹¹ 17β-estradiol to 4-hydroxyestradiol
a catechol estrogen metabolite that can form DNA adducts and has been implicated in estrogen-related cancer risk. Reduced CYP1B1 activity from R469W alters the balance of estrogen metabolites, though the clinical cardiovascular and cancer implications of carrier status are less well characterized than the glaucoma association.

Practical Implications

For homozygous carriers (AA genotype), PCG typically presents within the first year of life with symptoms including tearing, photophobia, blepharospasm, and cloudy corneas. Early pediatric ophthalmology evaluation is essential. Surgical treatment — goniotomy or trabeculotomy — is the mainstay of therapy and has a high success rate when performed early. Genetic confirmation allows targeted family counseling in consanguineous families.

For heterozygous carriers (one A allele), personal glaucoma risk is not elevated. However, if both parents carry a CYP1B1 pathogenic variant, each child has a 25% chance of inheriting two pathogenic copies and developing PCG.

The globally rare frequency of R469W (~0.005% overall) rises substantially in consanguineous Middle Eastern and South Asian populations where the variant originated. Genetic screening of at-risk families enables earlier diagnosis and better outcomes for affected children.

Interactions

The R469W variant occurs in the same gene as many other CYP1B1 pathogenic mutations. Compound heterozygosity — one R469W allele plus a different CYP1B1 pathogenic variant on the other chromosome — can also cause PCG and is clinically equivalent to R469W homozygosity. The most common co-occurring mutations in Middle Eastern populations are G61E (p.Gly61Glu) and D374N (p.Asp374Asn). Modifier loci elsewhere in the genome may suppress disease expression in some carriers, which explains documented incomplete penetrance in family studies.

Every gram of protein you eat generates ammonia as a byproduct of amino acid catabolism. Left unchecked, ammonia is neurotoxic — even modest elevations cause brain swelling, seizures, and coma. The urea cycle exists specifically to neutralize this threat, converting ammonia into urea for renal excretion across five enzymatic steps. Step four is catalysed by argininosuccinate lyase¹¹ argininosuccinate lyase
ASL — encoded by the ASL gene on chromosome 7q11.21. The enzyme cleaves argininosuccinate into arginine and fumarate, regenerating the arginine used by arginase in the final urea cycle step. The rs374304304 variant (c.280C>T) swaps a cysteine for an arginine at position 94 of the ASL protein, reducing enzyme activity to approximately 12% of normal and placing the gene squarely in the category of established pathogenic variants for argininosuccinic aciduria²² argininosuccinic aciduria
ASLD — also called argininosuccinate lyase deficiency. The second most common urea cycle disorder, with a prevalence of ~1 in 70,000 live births globally (ASLD).

The Mechanism

The p.Arg94Cys substitution replaces a positively charged arginine with a cysteine at a structurally conserved residue of the ASL tetramer interface. Cell-based assays³³ Cell-based assays
Inauen KV et al. Effect of cysteamine on mutant ASL proteins with cysteine for arginine substitutions. Mol Diagn Ther, 2016 showed that the Arg94Cys enzyme retains only approximately 12% of wild-type catalytic activity. The substitution introduces a free thiol group where none normally exists, disrupting the active-site geometry required for argininosuccinate cleavage. Interestingly, treatment with cysteamine — a compound that chemically reacts with free cysteines — increased Arg94Cys ASL activity by 64% in these assays, pointing toward the cysteine residue as the proximate functional defect and suggesting a potential avenue for pharmacological rescue.

Beyond its role in ureagenesis, ASL also participates in endothelial nitric oxide synthesis. The enzyme channels arginine directly to nitric oxide synthase (NOS) through a protein–protein interaction. In ASLD, this channelling defect⁴⁴ channelling defect
Kho J et al. Argininosuccinate lyase deficiency causes an endothelial-dependent form of hypertension. Am J Hum Genet, 2018 reduces local NO production in blood vessel walls independently of circulating arginine levels, causing endothelial dysfunction and a form of hypertension that does not respond reliably to arginine supplementation alone.

The Evidence

ASLD was classified in GeneReviews and ClinVar as an established pathogenic condition decades before rs374304304 was formally catalogued. ClinVar (VCV000092359) lists the Arg94Cys variant as Pathogenic/Likely pathogenic with criteria provided by ten independent diagnostic laboratories — Baylor Genetics, Fulgent, GeneDx, Labcorp Genetics (Invitae), LabCorp Women's Health, Natera, Myriad Genetics, Revvity Omics, Eurofins Ntd, and Sinai Health System — with no classification conflicts. The variant is associated exclusively with argininosuccinic aciduria.

Nagamani et al.⁵⁵ Nagamani et al.
Nagamani SC, Erez A, Lee B. Argininosuccinate lyase deficiency. Genet Med, 2012 reviewed the full clinical spectrum of ASLD: neonatal-onset with life-threatening hyperammonemia (ammonia ≥1000 µmol/L without treatment) in the most severe genotypes, and late-onset with episodic hyperammonemia triggered by illness or stress in milder cases. Critically, there is no reliable genotype–phenotype correlation — enzyme activity alone does not predict disease severity, making the clinical course difficult to forecast from the variant alone.

Long-term complications extend well beyond hyperammonemia. Burrage et al.⁶⁶ Burrage et al.
Burrage LC et al. Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency. JCI Insight, 2020 found elevated ALT in 37% of ASLD patients and documented liver fibrosis on histology even when aminotransferases were normal. A 2023 retrospective study⁷⁷ 2023 retrospective study
Elkhateeb N et al. Natural history of epilepsy in argininosuccinic aciduria. Epilepsia, 2023 found epilepsy in 60% of ASLD patients, with 27% showing pharmacoresistant seizures. Systemic hypertension was characterised mechanistically in an endothelial-specific mouse model⁸⁸ endothelial-specific mouse model
Kho J et al., Am J Hum Genet, 2018 as a direct consequence of impaired endothelial nitric oxide production — a systemic manifestation that is not corrected by conventional dietary management.

Practical Actions

For biallelic ASLD (homozygous or compound heterozygous), long-term management requires protein restriction — dietary protein is typically limited to the minimum requirement for age, with the remainder of energy needs supplied as non-protein calories. Arginine base supplementation (100–300 mg/kg/day in children; 2.2–5.5 g/m²/day in adults) replenishes the arginine that would normally be released by the intact urea cycle. Arginine base is preferred over arginine hydrochloride to avoid metabolic acidosis with chronic use.

Affected individuals require metabolic monitoring every 2–4 weeks in the first year, tapering to every 3–4 months in stable older children and adults: plasma ammonia, plasma amino acids (particularly argininosuccinate and citrulline), liver function tests (ALT, AST, albumin, INR), blood pressure, and serum potassium. Liver ultrasound every 1–2 years is recommended given the high rate of subclinical liver disease.

Acute hyperammonemic crises require emergency management — protein is immediately stopped, intravenous glucose and lipids provide energy, and intravenous nitrogen scavengers (sodium benzoate/phenylacetate) are used. Severe cases may require dialysis.

For heterozygous carriers, no metabolic treatment is indicated. The primary significance is reproductive.

Interactions

ASLD is caused by biallelic loss of ASL function — most patients are compound heterozygous for two different pathogenic ASL variants rather than homozygous for a single variant. When a carrier of Arg94Cys (CT genotype) has a partner who also carries any pathogenic ASL variant, each pregnancy faces a 25% risk of ASLD. The combination of two pathogenic ASL alleles — regardless of which specific variants — determines clinical disease. Cascade carrier testing of first-degree relatives of any confirmed ASLD patient is therefore standard practice.

Every statin ever prescribed targets one protein: HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the cholesterol biosynthesis pathway. What most people don't know is that the HMGCR gene produces two versions of its own enzyme — a full-length, fully active form and a shorter variant missing 53 amino acids from the catalytic domain, encoded by a transcript that skips exon 13. How much of each version your cells make is under tight genetic control, and rs3846663 tags the haplotype that governs that balance.

The Mechanism

rs3846663 sits in an intron of HMGCR on chromosome 5 (GRCh38 position 75,359,901). It is not itself the functional variant, but serves as a proxy — in tight linkage disequilibrium¹¹ linkage disequilibrium
LD: two variants so commonly inherited together that one reliably predicts the other (r²=0.82–0.93) with rs3846662, a SNP located 47 base pairs downstream of exon 13 in intron 13.

The rs3846662 variant directly regulates the splicing factor HNRNPA1²² HNRNPA1
a nuclear RNA-binding protein that promotes skipping of entire exons during mRNA processing. The rs3846662 A allele disrupts an SRSF1 binding site while preserving HNRNPA1 binding, causing the spliceosome to skip exon 13 more frequently. The resulting HMGCRΔ13 transcript, lacking 53 amino acids in the catalytic domain, encodes an enzymatically inactive HMG-CoA reductase.

The T allele at rs3846663 travels with the rs3846662 G allele — the allele that promotes exon 13 retention, yielding more full-length, catalytically active HMGCR. More active enzyme means more cholesterol is synthesized endogenously, and circulating LDL-C levels rise correspondingly. In vitro studies in human lymphoblastoid cells confirm that homozygosity for the minor/G haplotype is associated with up to 2.2-fold lower expression of the alternatively spliced HMGCRΔ13 transcript.

The Evidence

The founding GWAS was conducted by Burkhardt et al. (2008)³³ Burkhardt et al. (2008) in the isolated Kosraean population of Micronesia (n=2,346) and validated in the Diabetes Genetics Initiative Caucasian cohort (~2,758 subjects). rs3846663 reached genome-wide significance for LDL-C association (combined P=7×10⁻¹⁰). Three SNPs in tight LD — rs7703051, rs12654264, and rs3846663 — all met the genome-wide threshold, with a functional splicing experiment in lymphoblast minigene systems confirming that the linked rs3846662 directly controls exon 13 inclusion.

The functional consequence for statin response was characterized in the CAP study⁴⁴ CAP study
Medina et al. Circulation 2008: Alternative splicing of HMGCR is associated with plasma LDL-C response to simvastatin (Cholesterol and Pharmacogenetics, n=170 lymphoblastoid cell lines from simvastatin-treated individuals). The alternatively spliced HMGCRΔ13 transcript explained 6–15% of the variance in statin-induced LDL-C reduction — substantially more than genotype alone (<2%). A higher proportion of the Δ13 transcript (driven by the A-haplotype protective alleles) meant the cells already had less active HMGCR before statin exposure, leaving proportionally less enzyme activity to inhibit.

Sex-dependent effects emerged in a study of French-Canadian familial hypercholesterolemia patients by Tremblay et al. (2016)⁵⁵ Tremblay et al. (2016). Women homozygous for the rs3846662 AA genotype (the exon-skipping-promoting haplotype, which corresponds to the CC genotype at rs3846663) showed significantly greater LDL-C reduction on statins (46.2% vs 38.4% in AA women), while no significant sex-specific difference was observed in men. This suggests the exon 13 splicing mechanism interacts with hormonal physiology in ways that modify statin pharmacodynamics.

At the population level, the landmark Ference et al. NEJM study (2016)⁶⁶ Ference et al. NEJM study (2016) used HMGCR variant scores across 112,772 participants (14 studies, 14,120 CVD events) to show that genetically lower LDL-C through HMGCR variants reduces cardiovascular risk with an OR of 0.81 (95% CI 0.72–0.90) per 10 mg/dL reduction — essentially identical to the observed benefit of pharmacological statin therapy — confirming the LDL-causal model.

Practical Actions

Carriers of the T allele (CT or TT genotype at rs3846663) have relatively more full-length HMGCR expression and correspondingly higher baseline LDL-C. This does not mean statins don't work — they do, but the mechanism differs. With less pre-existing Δ13-driven enzyme suppression, T allele carriers may require higher statin doses to achieve the same LDL-C reduction as CC individuals. Monitoring LDL-C response at 6–8 weeks after statin initiation and adjusting dose to target is therefore especially valuable for TT homozygotes.

CC homozygotes tend to have lower baseline LDL-C and may achieve larger proportional LDL-C reductions on statins, particularly women, due to the amplified exon-skipping effect. Standard statin dosing is generally adequate.

Interactions

rs3846663 is a proxy for the rs3846662-defined H7 haplotype (rs17244841 / rs3846662 / rs17238540), which is the core functional haplotype characterized in statin response studies. Compound analysis across HMGCR haplotypes (H2 + H7 together) shows further attenuation of statin response compared to either haplotype alone, suggesting additive effects of multiple HMGCR splicing-regulatory SNPs. A gene-gene interaction between the LIPC locus (rs1532085) and the HMGCR region has been reported in multi-ethnic data, explaining an additional 0.2–1.1% of HDL-C variance beyond either SNP alone.

When a genetic test returns a "variant of uncertain significance" (VUS) in a cardiomyopathy gene, it sits in one of medicine's most difficult grey zones: clinically actionable enough to flag, not conclusive enough to act on alone. rs397516394 — a missense substitution that converts methionine to valine at position 281 of cardiac alpha-tropomyosin (encoded by TPM1) — is precisely this kind of result. It appears on HCM gene panels because TPM1 is a well-established HCM gene and position 281 is in a biologically meaningful region. Yet as of 2026, five independent clinical laboratories have evaluated this variant and all five reached the same conclusion: uncertain significance¹¹ uncertain significance
Variants of uncertain significance (VUS) cannot be classified as pathogenic or benign because available evidence is insufficient; they are neither reassuring nor alarming in isolation and require clinical context and family studies for interpretation.

The Mechanism

Cardiac alpha-tropomyosin is a 284-amino acid coiled-coil protein that runs along the length of the actin thin filament in cardiac muscle. Its function is regulatory: at diastolic (low) calcium concentrations, tropomyosin occupies the "blocked" position that sterically prevents myosin from binding actin. When calcium rises during a heartbeat, troponin pulls tropomyosin aside to expose myosin-binding sites, enabling contraction. When this system is disrupted — either by increased flexibility or altered calcium sensitivity — the consequence is cardiac hypertrophy, diastolic dysfunction, and arrhythmia risk, the hallmarks of hypertrophic cardiomyopathy²² hypertrophic cardiomyopathy
HCM affects ~1:500 people and is the most common inherited cardiac condition; it is the leading cause of sudden cardiac death in people under 35.

Position 281 (methionine) sits near the C-terminus of tropomyosin, a region involved in head-to-tail overlap with adjacent tropomyosin dimers along the actin filament. An adjacent substitution at this residue — Met281Thr, a different amino acid swap at the same codon — has been studied in mechanistic assays as a dilated cardiomyopathy (DCM) variant³³ dilated cardiomyopathy (DCM) variant
DCM is the opposite of HCM: the ventricle becomes dilated and hypocontractile rather than thick and hypercontractile; DCM-associated tropomyosin mutations reduce Ca²⁺ sensitivity whereas HCM mutations increase it. The Met→Val substitution at rs397516394 changes the amino acid from a flexible sulfur-containing side chain to a small branched hydrophobic residue; the net structural impact on tropomyosin flexibility and calcium sensitivity has not been reported in published functional studies.

The Evidence

The evidence base for rs397516394 is thin and indirect:

ClinVar classification: Five clinical laboratories⁴⁴ Five clinical laboratories
ClinVar VCV000043448; submitters include Ambry Genetics, GeneDx, Laboratory for Molecular Medicine (Mass General Brigham), Labcorp Genetics (Invitae), and Color Diagnostics have independently classified Met281Val as uncertain significance. In silico analysis by multiple submitters suggested the variant may be tolerated (PolyPhen-2 prediction of low pathogenicity). The only pointer toward clinical relevance is the observation that "other variants that disrupt this residue have been determined to be pathogenic" — meaning the Met281 position has functional importance, but the Val substitution specifically has not been proven to share that importance.

Population frequency: The G allele (Val) appears in approximately 6 per million alleles in gnomAD exomes — not absent, but consistent with a disease-relevant rare variant. By comparison, confirmed pathogenic TPM1 variants like E180G are absent from gnomAD entirely.

Gene context: Walsh et al., 2017⁵⁵ Walsh et al., 2017
Walsh R et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples; Genet Med 2017 applied rigorous statistical standards to cardiomyopathy genes and found that many rare missense variants in sarcomeric genes previously treated as pathogenic do not meet evidence thresholds. TPM1 missense VUSs — including variants at positions where other substitutions cause disease — are a well-recognized challenge in clinical HCM genetics.

The Gupte et al. benchmark: Mechanistic work on seven TPM1 variants⁶⁶ Mechanistic work on seven TPM1 variants
Gupte et al. J Biol Chem 2015 — examined Ca²⁺ sensitivity of human β-cardiac myosin ATPase; HCM-associated TPM1 mutations showed hypersensitivity, DCM mutations showed hyposensitivity included M281T (the adjacent threonine substitution). Whether Met281Val follows the same mechanistic pattern has not been published. The absence of functional data is a key reason the variant remains unclassified.

Clinical observations: The variant has been identified in individuals undergoing HCM genetic testing — but given the prevalence of HCM (~1:500) and the high background rate of VUS findings in cardiomyopathy panels (~15% of probands per Alfares et al.), coincidental ascertainment without causation cannot be excluded. No published family co-segregation data, functional studies, or case series specifically characterizing Met281Val have been identified.

Practical Actions

A TPM1 VUS result has specific implications for clinical management — different from both a confirmed pathogenic finding and a benign result. Current HCM guidelines (AHA/ACC and ESC) recommend against making diagnostic or treatment decisions based on a VUS alone. However, the presence of a VUS in a disease-relevant gene warrants cardiac surveillance and family investigation to gather additional evidence for future reclassification.

If this result appears in the setting of clinical HCM (confirmed cardiac imaging findings), it strengthens but does not prove the genetic basis. If this result appears incidentally in someone without HCM features, it requires surveillance rather than immediate intervention.

Interactions

Met281Val is in the same gene and biological context as confirmed pathogenic TPM1 variants: E180G (rs104894502) at position 180 and D175N (rs104894503) at position 175. All three are ultra-rare missense changes in cardiac alpha-tropomyosin; the confirmed variants both increase calcium sensitivity through reduced protein rigidity. Whether Met281Val shares this mechanism or the opposite (DCM-type hyposensitivity, as seen with Met281Thr) is a key open question. Other sarcomeric HCM genes — MYBPC3 (rs36211723 and others), MYH7, TNNT2 — contribute independently to HCM risk and are not captured by this result.

Biotinidase¹¹ Biotinidase
Encoded by the BTD gene at chromosome 3p25.1; the enzyme recycles biotin (vitamin B7) from biocytin, the product of biotin-dependent carboxylase breakdown is the enzyme responsible for regenerating free biotin from protein-bound forms in the diet and from normal cellular protein turnover. Without it, the body cannot recycle its biotin supply — a cofactor that four essential carboxylase enzymes depend on for amino acid catabolism, gluconeogenesis, and fatty acid synthesis. When biotinidase is absent or severely reduced, biotin deficiency accumulates regardless of dietary intake, because the bound form simply cannot be freed for reuse.

The rs398123138 variant is a 5-base pair deletion (c.1448_1452delGGATG) in exon 4 of BTD that shifts the reading frame at codon 483, producing a premature stop signal at position 509 (p.Gly503Aspfs*6). The final 41 amino acids of the mature biotinidase protein are replaced by 6 aberrant residues before translation terminates, eliminating the C-terminal domain critical for enzyme function. ClinVar classifies this variant as pathogenic for biotinidase deficiency²² biotinidase deficiency
OMIM 253260; autosomal recessive inborn error of biotin metabolism; combined incidence 1 in 61,067 newborns; carrier frequency approximately 1 in 120 with consensus from five independent clinical genetics laboratories.

The Mechanism

Biotinidase cleaves biocytin — the biotinyl-lysine product released during carboxylase protein turnover — to regenerate free biotin. Free biotin is then re-attached to the apocarboxylase enzymes that power four critical metabolic reactions: pyruvate carboxylase (gluconeogenesis), acetyl-CoA carboxylase (fatty acid synthesis), propionyl-CoA carboxylase (amino acid catabolism), and methylcrotonyl-CoA carboxylase (leucine catabolism). When biotinidase is absent, biocytin accumulates in urine, free biotin is progressively depleted, and all four carboxylases lose their cofactor. The frameshift in this variant destroys the C-terminal region of biotinidase, which structural studies suggest is essential for substrate binding and catalytic activity, resulting in complete loss of enzyme function — categorised as profound biotinidase deficiency (<10% of normal enzyme activity).

The inheritance pattern is autosomal recessive. One functional copy of BTD is sufficient to maintain normal biotin recycling; carriers with a single defective allele are clinically unaffected under normal conditions. Biallelic loss — two pathogenic BTD alleles (homozygous or compound heterozygous) — is required to produce the deficiency phenotype.

The Evidence

Biotinidase deficiency was first described in the early 1980s and neonatal screening has been universal in many countries since the mid-1990s³³ universal in many countries since the mid-1990s
Newborn screening identifies biotinidase deficiency by enzyme activity assay on dried blood spot; normal activity is defined as 100%; profound deficiency <10%; partial deficiency 10–30%. Untreated profound deficiency typically presents between one week and ten years of age (mean 3.5 months) with neurological deterioration — seizures, hypotonia, developmental delay, alopecia, skin rash, and sensorineural hearing loss. Without treatment, the disorder is progressive and potentially fatal. With early biotin supplementation, the prognosis is excellent⁴⁴ excellent
Wolf 2012 (PMID 22698809): two-decade NBS follow-up — all NBS-detected patients treated early are developmentally normal; late-treated patients who already had symptoms retain sensorineural hearing loss and optic atrophy even after biotin normalises.

The BTD c.1448_1452del frameshift has been observed in affected individuals with confirmed biotinidase deficiency and submitted to ClinVar by five independent laboratories including Baylor Genetics, Labcorp Genetics, CENTOGENE, Eurofins, and Counsyl — achieving 2-star "multiple submitters, no conflicts" review status. Allele frequency in population databases (gnomAD) is effectively zero, consistent with the extreme rarity expected for a pathogenic null allele in an autosomal recessive disorder with combined incidence of 1 in 61,067.

Practical Implications

For homozygotes or compound heterozygotes (two pathogenic BTD alleles): oral free biotin supplementation fully corrects the biochemical defect. Profound deficiency requires 5–10 mg/day of free D-biotin; partial deficiency (10–30% residual enzyme activity) is typically managed with 2.5–10 mg/day. Treatment is lifelong — biotinidase cannot be restored — but biotin at these pharmacologic doses has no known toxicity. Early diagnosis through newborn screening is critical: symptoms that develop before biotin is started (particularly sensorineural hearing loss) may be irreversible even after biotin normalises.

For heterozygous carriers, no supplementation is required. The single functional BTD copy maintains sufficient enzyme activity for normal biotin recycling under typical dietary conditions. The practical significance of carrier status is reproductive: two carrier parents face a 25% per-pregnancy risk of having an affected child.

Interactions

Biotinidase deficiency interacts directly with other BTD pathogenic variants in a compound heterozygous pattern. Related variants rs397507172, rs397507173, and rs397507174 are additional pathogenic alleles at the BTD locus; a carrier of c.1448_1452del who also carries one of these variants on the other chromosome would have biallelic BTD dysfunction and profound deficiency. The practical implication is that partner carrier testing should cover the full BTD coding sequence, not just this single variant, to accurately calculate offspring risk.

High-dose biotin supplementation (≥5 mg/day) as used in treatment can interfere with biotin-streptavidin immunoassays — a technology used in many commercial laboratory tests including thyroid hormones (TSH, free T4), cardiac troponins, and PTH. Patients on pharmacologic biotin should inform their treating physicians and pause biotin for 2–3 days before immunoassay- based blood tests to avoid spurious results.

Plasminogen is one of the body's most versatile proteases-in-waiting. Synthesised primarily in the liver, it circulates as an inactive zymogen until activated by tissue plasminogen activator (tPA) or urokinase (uPA)¹¹ tissue plasminogen activator (tPA) or urokinase (uPA)
serine proteases released at sites of injury, infection, or thrombosis to form plasmin — the active enzyme that dissolves fibrin clots, remodels damaged extracellular matrix, recruits macrophages to sites of inflammation, and regulates the complement cascade. Variants across the PLG locus on chromosome 6q26 are among the strongest known genetic determinants of circulating plasminogen levels and downstream fibrinolytic capacity.

Rs4252185 sits 66 base pairs into the first intron of PLG (NM_000301.5:c.49+66T>C), on the plus strand of chromosome 6 at position 160702419 (GRCh38). The C allele is the minor variant, occurring in approximately 9% of Europeans but nearly absent in East Asian populations (under 0.1%), a pattern of population stratification characteristic of PLG-region haplotypes under selection pressure. This early-intron position is notable: intron 1 frequently harbours regulatory elements — branch-point sequences, intronic enhancers, and early splice signals — that can influence transcription initiation and pre-mRNA processing efficiency.

The Mechanism

Rs4252185 is classified as an intronic variant with no protein-coding consequence. The C allele has a low CADD score of 0.73²² CADD score of 0.73
a composite deleteriousness score where scores below 10 suggest limited expected functional impact at the individual variant level and a negative GERP conservation score (-2.70), indicating the position is not under strong evolutionary constraint across mammals.

Despite the modest predicted functional impact, the PLG locus is known to exert strong haplotype-level effects on plasminogen levels. Ma et al. 2014 demonstrated in a GWAS of over 3,000 individuals³³ Ma et al. 2014 demonstrated in a GWAS of over 3,000 individuals
published in Blood, the leading haematology journal that 9 of 11 genome-wide significant loci for plasma plasminogen levels cluster near PLG/LPA on chr6q26. Rs4252185 sits within the same genomic neighbourhood, and its C allele shows the European-enriched, East-Asian-depleted pattern typical of the PLG regulatory haplotype documented in that study. Whether rs4252185 is itself causal or in linkage disequilibrium with a functional regulatory variant elsewhere in the locus has not been directly established.

The Evidence

Rs4252185 has been captured in genome-wide analyses of coronary artery disease. Nurnberg et al. 2016⁴⁴ Nurnberg et al. 2016
a functional genomics analysis of 58 established CAD GWAS loci published in Circulation Research and Charmet et al. 2018⁵⁵ Charmet et al. 2018
a GWAS of CAD in patients with type 1 diabetes, published in Cardiovascular Diabetology both include the PLG locus in cardiovascular genetic analyses. The biological rationale is direct: plasminogen is essential for fibrinolytic clot dissolution in coronary arteries, and reduced plasminogen activity accelerates thrombotic occlusion.

The broader PLG-locus biology is well characterised through related variants. Plasminogen deficiency in mice causes spontaneous chronic otitis media in 100% of animals within 18 weeks⁶⁶ spontaneous chronic otitis media in 100% of animals within 18 weeks
with fibrin deposition, bacterial colonisation, and persistent neutrophil/macrophage infiltration in the middle ear, establishing fibrinolytic clearance as rate-limiting for middle ear health. Plasminogen also plays a direct role in innate immunity: Ploplis & Castellino 2014⁷⁷ Ploplis & Castellino 2014 showed that plasminogen-deficient mice have 60–90% reduced macrophage phagocytic uptake of apoptotic cells and pathogens. Barthel et al. 2014⁸⁸ Barthel et al. 2014 demonstrated that plasmin cleaves complement fragment iC3b, providing an alternative complement regulatory pathway independent of cellular cofactors. Together, these findings place PLG at the intersection of fibrinolysis, macrophage function, and complement regulation.

The evidence for rs4252185 itself is currently at the GWAS-signal level — the variant appears in cardiovascular genetic datasets but has not been independently validated in expression studies or functional assays. The evidence level is therefore emerging for this specific SNP.

Practical Actions

For carriers of the C allele, the primary actionable signal from this PLG locus variant is cardiovascular: any factor that impairs plasminogen-dependent fibrinolysis (smoking, elevated PAI-1, coagulation disorders) compounds the potential effect of reduced PLG activity. Cardiovascular risk monitoring is warranted — particularly in the presence of other cardiovascular risk factors.

Because the C allele is rare in a homozygous state (under 1%), the CC genotype warrants the most specific follow-up. TC heterozygotes have a modest signal that does not change clinical management unless combined with other PLG-region variants or independent cardiovascular risk factors.

Interactions

Rs4252185 sits in the same PLG haplotype block as rs4252130 (a periodontitis- associated intronic variant) and is in the same gene as the rare pathogenic rs73015965 (K38E, p.Lys38Glu), which causes type I plasminogen deficiency. Carriers of both a common PLG regulatory variant (rs4252185 C, rs4252130 C) and the rare loss-of-function allele (rs73015965 G) would have lower total plasminogen output than either variant alone predicts — though no published human data quantify this compound effect directly.

The LPA gene immediately adjacent on 6q26 encodes lipoprotein(a), which is structurally homologous to plasminogen and competes for plasminogen receptor sites. High Lp(a) levels can interfere with plasmin-mediated fibrinolysis, so carriers of C alleles at PLG-region variants with concurrent high Lp(a) may have compounded vascular risk.

TPH2 (tryptophan hydroxylase 2) is the rate-limiting enzyme¹¹ rate-limiting enzyme
The slowest step in a biochemical pathway, which determines the overall speed of production for serotonin synthesis in the brain. Unlike its cousin TPH1, which makes serotonin in the gut and other peripheral tissues, TPH2 works exclusively in neurons—particularly in the raphe nuclei²² raphe nuclei
Clusters of serotonin-producing neurons in the brainstem that project throughout the brain, regulating mood, sleep, and emotional processing of the midbrain. The rs4570625 variant sits 703 base pairs upstream of the TPH2 gene's start site, in a regulatory region that controls how much enzyme gets made.

The Mechanism

This G>T substitution affects a promoter region where transcription factors³³ transcription factors
Proteins that bind to DNA and control gene expression by turning genes on or off bind to initiate TPH2 gene expression. In vitro studies suggest the T allele is associated with reduced TPH2 promoter activity, potentially lowering serotonin synthesis capacity. Brain imaging studies have found that carriers of different alleles show altered reactivity in the amygdala⁴⁴ amygdala
The brain's emotional processing center, especially for fear and threat detection and ventromedial prefrontal cortex⁵⁵ ventromedial prefrontal cortex
Brain region involved in emotional regulation, decision-making, and inhibiting negative emotions during emotional tasks.

The Evidence

The most comprehensive evidence comes from a 2012 meta-analysis of 27 studies including 13,041 cases and 11,568 controls, which found rs4570625 significantly associated with major depressive disorder (summary OR = 0.83, 95% CI: 0.73–0.96) . However, the direction of risk has been contentious.

A 2017 Estonian population study found that TT homozygous males reported less aggressive behavior, lower scores on maladaptive impulsivity, fewer ADHD symptoms, and lower rates of anxiety disorders compared to G-allele carriers .

Yet other research points in the opposite direction.

A 2023 pharmacological fMRI study found that specifically GG carriers experienced anxiogenic effects during acute tryptophan depletion (which transiently lowers serotonin), while TT carriers did not .

The G-allele has been suggested to relate to hypofunction of tryptophan hydroxylase and lower serotonin synthesis rates , though the functional implications remain incompletely understood.

The clearest pattern emerges when considering gene-environment interactions⁶⁶ gene-environment interactions
When genetic variants influence how a person responds to environmental factors like stress, creating different outcomes than either factor alone.

Single marker analyses showed significant gene-by-environment interactions with rs4570625 on depressive symptoms .

An interaction between TPH2 rs4570625 and BDNF Val66Met yields two at-risk groups for difficulty inhibiting negative emotional content: BDNF Val/Val combined with TPH2 G/G, and BDNF Met carriers combined with TPH2 T allele .

Practical Implications

Because the functional effects of this variant depend heavily on genetic background and environmental context, the practical guidance is less about the variant itself and more about understanding your vulnerability patterns. If you're a GG carrier, you may be more susceptible to mood changes when serotonin synthesis is temporarily compromised—for example, during periods of high stress, poor sleep, or low dietary tryptophan intake. TT carriers appear more resilient to transient serotonin fluctuations but may have other vulnerabilities depending on interactions with variants in genes like BDNF.

The key actionable insight is that serotonin synthesis depends on adequate tryptophan (the dietary precursor), cofactors like vitamin B6⁷⁷ vitamin B6
Required for the enzyme that converts 5-hydroxytryptophan to serotonin, and iron (required for TPH2 enzyme function). Unlike some genetic variants where supplementation directly addresses the problem, TPH2 variants don't create a specific nutrient deficiency—they affect the efficiency of the enzyme that uses those nutrients.

Interactions

The most well-documented interaction is with BDNF rs6265 (Val66Met). The combination of BDNF genotype and TPH2 rs4570625 genotype creates distinct emotional regulation profiles that neither variant predicts alone. Specifically, BDNF Val/Val + TPH2 GG shows impaired negative emotion inhibition, as does BDNF Met + TPH2 T-carrier status, suggesting epistasis⁸⁸ epistasis
When the effect of one gene variant depends on the presence of another gene variant between these serotonergic and neurotrophic pathways.

Within the TPH2 gene itself, rs4570625 is in linkage disequilibrium⁹⁹ linkage disequilibrium
When variants are inherited together more often than would be expected by chance, forming haplotype blocks with rs11178997, rs1386494, and rs7305115, forming haplotypes that collectively influence TPH2 expression and psychiatric risk more than any single variant.

For those interested in understanding their broader serotonergic genetics, variants in SLC6A4 (serotonin transporter), HTR1A and HTR2A (serotonin receptors), and MAOA (serotonin degradation) interact with TPH2 to shape overall serotonergic tone and psychiatric vulnerability.

The rs4888378 variant sits within an intron of CFDP1 (Craniofacial Development Protein 1) on chromosome 16q23, but the functionally relevant gene it controls is a neighbor: BCAR1 (Breast Cancer Anti-Estrogen Resistance 1¹¹ Breast Cancer Anti-Estrogen Resistance 1
a scaffold protein originally characterised in drug-resistant breast cancer but now recognised as a regulator of endothelial cell migration and vascular smooth muscle remodelling). GWAS analysis identified this locus as one of 64 novel genome-wide-significant loci for coronary artery disease in a study spanning over 82,000 subjects, with the G allele conferring risk (P=6×10⁻¹⁵).

The Mechanism

The rs4888378 position falls within a regulatory element that binds the transcription factor FOXA (Forkhead Box A)²² FOXA (Forkhead Box A)
a pioneer transcription factor that opens chromatin and activates gene expression in liver, vascular, and epithelial tissues. Electrophoretic mobility shift assays show allele-specific protein binding at this exact nucleotide: the A allele weakens FOXA recruitment, while the G allele supports it. The consequence is a large change in BCAR1 expression — luciferase reporter assays showed the A allele reduces BCAR1 promoter activity by 35% to 92% relative to the G allele (P values: 0.0057 and 4.0×10⁻²²).

BCAR1 (also called p130Cas) is a scaffold protein with 15 phosphorylation sites for Src family kinases. In vascular tissue it promotes endothelial cell migration, smooth muscle cell proliferation after arterial injury, and integrin-mediated signalling pathways that drive plaque development. Higher BCAR1 expression — the state produced by the G allele — accelerates the cellular programmes that thicken arterial walls and build atherosclerotic burden.

The Evidence

The initial GWAS discovery by Gertow et al. 2012³³ Gertow et al. 2012
Identification of the BCAR1-CFDP1-TMEM170A locus as a determinant of carotid intima-media thickness and coronary artery disease risk. Circ Cardiovasc Genet 2012 identified rs4888378 as the lead SNP for maximum carotid IMT in 3,430 Swedish subjects (IMPROVE study; discovery P=6.75×10⁻⁷), replicated in 11,590 subjects across five European cohorts. In two independent case-control samples totalling 13,591 and 82,297 subjects of European ancestry, the A allele was associated with lower coronary artery disease risk (OR 0.83, 95% CI 0.77–0.90, P=6.53×10⁻⁶; and OR 0.95, 95% CI 0.92–0.98, P=1.83×10⁻⁴). These are additive per-allele effects — each copy of the A allele lowers CAD risk incrementally.

The follow-up functional study by Boardman-Pretty et al. 2015⁴⁴ Boardman-Pretty et al. 2015
Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant. Circ Cardiovasc Genet 2015 narrowed 214 candidate regulatory variants in strong LD with rs4888378 to six by layering ENCODE regulatory annotations, then confirmed allele-specific FOXA binding and expression effects at rs4888378 itself. Crucially, the protective effect on IMT progression was sex-stratified: in the PLIC cohort, the AA genotype associated with slower IMT progression in women (P=0.04) but not in men, and meta-analysis across five cohorts confirmed the A allele's protective beta was significant only in women (β=-0.0047, P=1.63×10⁻⁴ versus P=0.068 in men). The sex-differential mechanism is not fully understood but may relate to oestrogen's interaction with FOXA-regulated vascular gene programmes.

The large-scale coronary artery disease signal was confirmed in a 2018 genome-wide study by van der Harst & Verweij⁵⁵ van der Harst & Verweij
Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ Res 2018, reaching genome-wide significance (P=6×10⁻¹⁵) — establishing this locus as a robust, replicated determinant of atherosclerotic burden, not just an initial association.

Practical Actions

The rs4888378 locus acts on the rate of subclinical atherosclerosis accumulation over decades. The G allele raises vascular BCAR1 expression, accelerating endothelial and smooth muscle remodelling processes. For GG carriers the most useful focus is on biomarkers that detect subclinical atherosclerosis before clinical events — carotid IMT measurement and coronary artery calcium scoring quantify exactly the burden that this locus influences. Controlling modifiable atherosclerosis drivers (LDL cholesterol, blood pressure, smoking, glycaemia) becomes proportionally more important when the genetic background is already pro-atherogenic. For women carrying risk genotypes, the evidence of sex-specific vulnerability at this locus strengthens the case for proactive vascular risk monitoring.

Interactions

This locus sits in a genomic cluster with TMEM170A and BCAR1 itself. The three genes share regulatory architecture, and expression quantitative trait loci analysis confirms BCAR1 as the vascular-relevant effector. CFDP1 and TMEM170A are expressed in the region but did not show the same vascular eQTL pattern in the Boardman-Pretty functional study. No epistatic interactions with other SNPs have been formally characterised for this locus, but co-occurring risk variants in lipid pathways (APOE, PCSK9, LPA) and blood pressure pathways would be expected to compound atherosclerotic burden additively.

Your FUT2 gene is the master switch for secretor status¹¹ secretor status
Whether you express ABO blood group antigens on mucosal surfaces and in saliva, tears, and intestinal mucus — a trait that fundamentally shapes your gut microbiome and immune landscape. rs492602 is a synonymous proxy variant that tags this biological divide: the G allele travels with the secretor phenotype, while the A allele travels with the non-secretor phenotype that arises from the nearby W143X nonsense mutation²² W143X nonsense mutation
rs601338 (G428A) creates a premature stop codon at amino acid 143 of FUT2, producing a truncated, non-functional enzyme; this is the primary FUT2 non-secretor variant in Europeans and Africans (rs601338). Although rs492602 itself is a silent coding change (alanine-68 codon remains alanine), it serves as a reliable genomic proxy for the functional variant in most populations.

The platform already tracks rs601338 in the vitamins-nutrients category, where the focus is on B12 absorption. This entry covers the orthogonal angle: the gut-skin axis³³ gut-skin axis
The bidirectional communication between the intestinal microbiome and skin immune function, increasingly recognised as a driver of inflammatory skin diseases including psoriasis and autoimmune susceptibility that rs492602 tags independently. The two entries address distinct clinical implications of the same underlying biology.

The Mechanism

FUT2 encodes alpha(1,2)-fucosyltransferase⁴⁴ alpha(1,2)-fucosyltransferase
An enzyme that adds the six-carbon sugar fucose to glycan chains on the surface of intestinal epithelial cells and into secreted mucus, creating the H antigen on which A and B blood group specificities are built. In secretors, fucosylated glycans line the gut wall and are shed into the intestinal lumen where they serve two purposes: attachment scaffolds for certain pathogens (and therefore pathogen resistance signals) and a dedicated carbon source for Bifidobacterium⁵⁵ Bifidobacterium
A genus of beneficial gut bacteria that have evolved specialised fucosidase enzymes to harvest fucose from host glycans as their primary food source in the gut species that have co-evolved with human secretors.

Non-secretors produce no functional FUT2 enzyme and therefore no mucosal fucosylated glycans. The immediate consequence is a profoundly altered intestinal microbiome — reduced Bifidobacterium richness and diversity, and an enrichment of bacteria that drive Th17-promoting inflammation. The gut of a non-secretor is structurally predisposed to a different immunological state from birth.

The Evidence

The secretor-microbiome connection was firmly established by Wacklin et al. 2011⁶⁶ Wacklin et al. 2011
Wacklin P et al. Secretor genotype (FUT2 gene) is strongly associated with the composition of Bifidobacteria in the human intestine. PLoS One, 2011: in 71 healthy volunteers, non-secretors showed significantly reduced bifidobacterial richness (p<0.0001) and several key species (B. bifidum, B. adolescentis, B. catenulatum) were absent or rare in non-secretors but common in secretors.

The link between FUT2 non-secretor status and Crohn's disease was established by a genome-wide association study in 4,100 Caucasian participants⁷⁷ 4,100 Caucasian participants
McGovern DPB et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet, 2010 reaching genome-wide significance (P=4.90×10⁻⁸). Mechanistically, Tong et al. 2014⁸⁸ Tong et al. 2014
Tong M et al. Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J, 2014 demonstrated that the non-secretor microbiome shows depleted amino-acid biosynthesis and enriched carbohydrate catabolism pathways, accompanied by sub-clinical mucosal inflammation in non-secretors even before disease onset.

The psoriasis association was identified in a Han Chinese case-control study Liu et al. 2021⁹⁹ Liu et al. 2021
Liu Y et al. Association of Polymorphisms of Metabolism-Related Genes with Psoriasis Vulgaris in Han Chinese. Biomed Res Int, 2021 of 1,030 psoriasis patients and 965 controls (OR=1.86, P=0.005). The association was stronger in individuals without the HLA-C*06:02 allele (OR=2.04), suggesting rs492602 contributes to psoriasis risk through a pathway partially independent of the canonical HLA-driven pathway. This is consistent with the gut-skin axis hypothesis: altered microbial composition drives systemic immune dysregulation that manifests in skin inflammation. Importantly, rs492602 sits in a genomic region with documented shared susceptibility for both psoriasis and Crohn's disease, supporting a common gut-immune mechanism.

A large Dutch microbiome GWAS Lopera-Maya et al. 2022¹⁰¹⁰ Lopera-Maya et al. 2022
Lopera-Maya EA et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat Genet, 2022 confirmed FUT2/secretor status as one of only two robust genome-wide significant genetic determinants of gut microbial composition, with a p-value below 1.89×10⁻¹⁰ — placing this among the most reproducible host-microbiome genetic associations in the human genome.

LD with rs601338: rs492602 is in strong LD with the functional W143X nonsense variant (rs601338) in European and African populations. The two variants are highly correlated, which is why rs492602 served as the GWAS tag SNP for B12 levels in the original Hazra et al. 2008 discovery. In East Asian populations, both variants are rare; the primary non-secretor allele there is rs1047781 (A385T). This entry focuses on the autoimmune and gut-skin axis biology; see the rs601338 entry for B12 absorption details.

Practical Actions

For non-secretors (AA), the gut-immune implications are the most actionable aspect of this variant. Supporting microbial diversity through prebiotic-rich foods and targeted Bifidobacterium probiotics can partially compensate for the structural deficit in mucosal glycan availability. Monitoring for early signs of gut inflammation is warranted given the elevated Crohn's risk.

For psoriasis specifically, the gut-skin axis implication means that gut microbiome health strategies may have downstream benefit for skin inflammation — though direct clinical evidence for probiotics modifying psoriasis severity in non-secretors specifically is not yet available.

Interactions

This variant is in strong LD with rs601338 (FUT2 W143X), which is separately catalogued for B12 metabolism. If you carry the A allele at rs492602, you very likely also carry the A (non-secretor) allele at rs601338. The two entries address different clinical angles of the same biology.

rs602662 (FUT2 S258G) is also in LD with this locus and shows similar Crohn's disease associations. In East Asian populations, rs1047781 (A385T) is the primary secretor-status determinant and should be checked in that ancestry context.